Spruce Biosciences Inc(SPRB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -40.87 | Insider Own | 12.62% | Shs Outstand | 2.8M | Perf Week | 9.97% |
| Market Cap | 0.14B | Forward P/E | 52.41 | EPS next Y | 103.48% | Insider Trans | - | Shs Float | 2.5M | Perf Month | -0.59% |
| Enterprise Value | 0.05B | PEG | 1.27 | EPS next Q | -5.68 | Inst Own | 66.95% | Short Float | 20.8% | Perf Quarter | 8.35% |
| Income | -0.05B | P/S | - | EPS this Y | 49.35% | Inst Trans | 40.02% | Short Ratio | 6.5 | Perf Half Y | -15.36% |
| Sales | 0.00B | P/B | 1.54 | EPS next 5Y | 41.25% | ROA | -82.38% | Short Interest | 0.52M | Perf YTD | -46.06% |
| Book/sh | 30.42 | P/C | 1.4 | EPS past 3/5Y | 29.85% 11.8% | ROE | -105.98% | 52W High | -64.28% ($131.54) | Perf Year | -62.26% |
| Cash/sh | 33.51 | P/FCF | - | Sales past 3/5Y | - | ROIC | -57.98% | 52W Low | 23.46% ($38.06) | Perf 3Y | -39.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 52.43% | Gross Margin | - | Volatility(W/M) | 6.07% 6.58% | Perf 5Y | -87.08% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 2.76 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.23 | EPS Q/Q | -90.92% | Profit Margin | - | RSI (14) | 53.72 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.23 | Sales Q/Q | - | SMA20 | 8.26% ($43.4) | Beta | 3.6 | Target Price | $148 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/12 | SMA50 | -6.48% ($50.25) | Rel Volume | 0.73 | Prev Close | $45.65 |
| Employees | 8 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | -15.37% - | SMA200 | -16.26% ($56.11) | Avg Volume(3M) | 0.08M | Price | $46.99 |
| IPO | 2020/10/9 | Option/Short | No/Yes | Trades | 1038 | Volume | 58,875 | Change | 2.94% |
🧬 Spruce Biosciences is a US-based clinical-stage biopharmaceutical company targeting rare endocrine and metabolic diseases. Its lead candidate, tildacerfont, is a CRF1 receptor antagonist that targets congenital adrenal hyperplasia, and the company is also developing an enzyme replacement therapy for Sanfilippo syndrome. Its hallmark is the concentration of resources on rare disease areas with high unmet medical needs.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded less than usual. That is 73% of its average volume.
SPRB has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +49.4% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.8% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #336 of 594 in the industry
Based on market cap of $135M.
CDXS#333 Codexis Inc $138M PER - 
MSLE#334 Satellos Bioscience Inc $138M PER - 
CMPX#335 Compass Therapeutics Inc $137M PER - SPRB#336 Spruce Biosciences Inc $135M PER - 
OTLK#337 Outlook Therapeutics Inc $133M PER - 
FAQ
What kind of company is SPRB?
SPRB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SPRB?
The market cap of SPRB is approximately $135M, ranking 4,308 within its sector.
What is the 52-week high and low for SPRB?
SPRB has recorded a 52-week high of $131.54 and a low of $38.06.
